Scientists probe why some blood disorder patients face higher clot danger
NCT ID NCT06480591
Summary
This study aims to understand why patients with a specific genetic mutation (CALR) in a rare blood cancer called MPN have a different risk of blood clots compared to patients with another common mutation (JAK2). Researchers will collect a single blood sample from about 35 adult patients with the CALR mutation to analyze their cells and compare them to other groups. The goal is to learn more about the biology of the disease to inform future treatments, but this study itself does not test a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Levine Cancer
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.